## AMENDMENTS TO THE CLAIMS

1. (Currently amended) A therapeutic delivery system for a host comprising:

a therapeutic agent; and

a sacromastigophoric organism containing said therapeutic agent through packaging and a gene encoding full length primate Hpr; said gene further comprising an inducible promoter and encoding a lysosomal targeting sequence.

2. (Currently amended) The system of claim 1 wherein said therapeutic agent is selected from the group consisting of: ~~a gene, an artificial chromosome, magnetic species, radioactive species, vitamins, nanocrystals, drugs,~~ drugs and prodrugs.

3. (Canceled)

4. (Previously presented) The system of claim 1 wherein the said organism is selected from the group consisting of Trypanosoma, Plasmodium, Amoeba, Giardia, Entamoeba, and Leishmania.

5-6 (Canceled)

7. (Currently amended) The system of claim 1 wherein expression of said ~~recombinant lytic factor~~ gene encoding full length primate Hpr is upregulated by [[a]] said promoter responsive to an induction species exogenous to both said organism and said host.

8. (Original) The system of claim 7 wherein said induction species is an antibiotic.

9-10 (Canceled)

11. (Currently amended) A therapeutic delivery system for a host comprising:

a trypanosome organism containing a gene encoding full length primate Hpr, expression of said gene is upregulated by a promoter responsive to an induction species exogenous to both said organism and said host; said gene further comprising a lysosomal targeting sequence.

12-40 (Canceled)

41. (Currently amended) A sacromastigophoric organism for delivery of a therapeutic agent obtained by the process comprising:

culturing sacromastigophoric organisms that have been transfected with an expression vector containing an expression cassette induced by a first exogenous species, the cassette comprising:

a first construct having a first inducible promoter controlling expression of a gene encoding primate Hpr protein also present in said construct; ~~said primate Hpr protein encoded by a gene present in said expression vector;~~ said protein further comprising a lysosomal targeting sequence.

42. (Canceled)